Survival time after early secondary recurrence of hepatocellular carcinoma cannot be generalized and can only be roughly assessed with statistical data. Some studies have shown that the 1-, 3-, 5-, and 10-year survival rates after secondary surgery are 81.0%, 40.3%, 19.4%, and 9.0%, respectively. Tumor recurrence occurs both early and late, and patients who recur within 1 year of surgery have a worse prognosis compared to those who recur 1 year after surgery. In addition, it has been shown that the 1-, 3-, 5-, and 10-year survival rates of hepatocellular carcinoma are substantially lower after three operations, which are 77.5%, 29.8%, 13.2%, and 6.61%, respectively, and the median survival time is 44 months. The above only discusses the data of surgical treatment after recurrence, but generally after recurrence, TACE, microwave, radiofrequency, freezing and anhydrous ethanol injection can also be chosen, and the therapeutic effect and prognosis of different treatment methods also vary. Special reminder: the statistics of 1, 3, 5 and 10 years survival rate, and median survival time only represent a relatively short period of time, usually around 12 months, and need to be judged specifically according to the individual’s physical condition, tumor recurrence, and the degree of effectiveness of later treatment. If the disease is relatively mild (e.g., isolated lesions, small number), previous treatment options (e.g., surgical resection, interventional therapy, etc.) can be used in combination with immune-targeted therapy, and most of the patients can achieve the prognosis of the first-diagnosed hepatocellular carcinoma, but the prognosis is still poorer than that of patients with the first-diagnosed disease. Patients with more serious recurrence of liver cancer, such as distant metastasis, multiple foci, and extensive infiltration, usually have lost the chance of surgical resection, and it is recommended to treat them aggressively with chemotherapy, radiotherapy, targeted therapy, immunotherapy, and interventional therapy, as well as symptomatic treatments to relieve the symptoms and prolong the survival period. The average survival time of patients may only be about 13 months. It is recommended that patients diagnosed with recurrent liver cancer should go to regular hospitals to evaluate their conditions and follow the doctor’s instructions to cooperate with the treatment, so as to control the progression of the disease and improve the prognosis of the patients.